CN100415241C - Medicinal composition for treating cardio-cerebrovascular diseases - Google Patents
Medicinal composition for treating cardio-cerebrovascular diseases Download PDFInfo
- Publication number
- CN100415241C CN100415241C CNB200310100813XA CN200310100813A CN100415241C CN 100415241 C CN100415241 C CN 100415241C CN B200310100813X A CNB200310100813X A CN B200310100813XA CN 200310100813 A CN200310100813 A CN 200310100813A CN 100415241 C CN100415241 C CN 100415241C
- Authority
- CN
- China
- Prior art keywords
- stem
- leaf
- radix ginseng
- salvianolic acid
- ginseng saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title abstract description 9
- 241000208340 Araliaceae Species 0.000 claims abstract description 82
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 82
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 82
- 235000008434 ginseng Nutrition 0.000 claims abstract description 82
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 62
- 229930182490 saponin Natural products 0.000 claims abstract description 62
- 150000007949 saponins Chemical class 0.000 claims abstract description 62
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 15
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 240000007164 Salvia officinalis Species 0.000 claims abstract 4
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 claims description 64
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 claims description 64
- 229930183842 salvianolic acid Natural products 0.000 claims description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000003463 adsorbent Substances 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 235000017276 Salvia Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 25
- 210000004369 blood Anatomy 0.000 abstract description 24
- 239000008280 blood Substances 0.000 abstract description 24
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 210000001124 body fluid Anatomy 0.000 abstract description 5
- 239000010839 body fluid Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 235000005412 red sage Nutrition 0.000 abstract 3
- 150000007965 phenolic acids Chemical class 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000012891 Ringer solution Substances 0.000 description 5
- 210000001168 carotid artery common Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960003371 protocatechualdehyde Drugs 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- -1 transfusion Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- ZMUQGGLSCIDPLS-UHFFFAOYSA-N Saponin 5 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C(C)(C)C5CCC34C)C2C1)C(=O)O ZMUQGGLSCIDPLS-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200310100813XA CN100415241C (en) | 2003-10-03 | 2003-10-03 | Medicinal composition for treating cardio-cerebrovascular diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200310100813XA CN100415241C (en) | 2003-10-03 | 2003-10-03 | Medicinal composition for treating cardio-cerebrovascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1528323A CN1528323A (en) | 2004-09-15 |
CN100415241C true CN100415241C (en) | 2008-09-03 |
Family
ID=34304086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200310100813XA Expired - Fee Related CN100415241C (en) | 2003-10-03 | 2003-10-03 | Medicinal composition for treating cardio-cerebrovascular diseases |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100415241C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101292987B (en) * | 2007-04-29 | 2010-06-30 | 北京本草天源药物研究院 | Pharmaceutical combination |
CN102058599B (en) * | 2009-11-17 | 2014-06-04 | 中国科学院上海药物研究所 | Salvianolate, and preparation method and application thereof |
WO2016033727A1 (en) * | 2014-09-01 | 2016-03-10 | 广州市香雪制药股份有限公司 | Medicine for preventing and treating vascular diseases and preparation method thereof |
CN105287670A (en) * | 2015-10-19 | 2016-02-03 | 遵义医学院 | Application of total saponins of Ginseng stems and leaves |
-
2003
- 2003-10-03 CN CNB200310100813XA patent/CN100415241C/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
双参注射液急性毒性与安全性实验的研究. 白明学等.河南中医药学刊,第15卷第2期. 2000 |
双参注射液急性毒性与安全性实验的研究. 白明学等.河南中医药学刊,第15卷第2期. 2000 * |
Also Published As
Publication number | Publication date |
---|---|
CN1528323A (en) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100447148C (en) | Cape jasmine extract , its preparing process and application | |
CN100415241C (en) | Medicinal composition for treating cardio-cerebrovascular diseases | |
CN101987112A (en) | Medicine composition for treating cardio-cerebrovascular diseases and preparation method thereof | |
CN102302681A (en) | Medicinal composition for treating cerebral infarction | |
CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
CN100408045C (en) | Medicinal composition for treating cardio-cerebro-vascular diseases | |
CN111558019B (en) | Traditional Chinese medicine composition with effects of benefiting qi, nourishing blood, regulating menstruation and relieving pain and preparation method and application thereof | |
CN1319549C (en) | Method for extracting general iridoid glycoside from 'Duyiwei' of Tibet medicine and application | |
CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
CN107126555A (en) | A kind of pigskin collagen small peptide active component composition of wound healing | |
CN101716253B (en) | Chinese medicinal preparation containing panax notoginseng, and preparation method thereof | |
CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
CN107638436B (en) | Application of pharmaceutical composition in preparation of medicine for treating subcutaneous hemorrhage | |
CN106361829B (en) | Traditional Chinese medicine composition and preparation for treating ischemic stroke and preparation method thereof | |
CN100381125C (en) | Cardiac and cerebral vascular disease treating medicinal composition | |
CN102940675A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
CN104367630A (en) | American ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
CN104367656A (en) | Hawthorn leaf-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
CN1562057A (en) | Medicinal composition for treating cardiocerobral diseases | |
CN102940676B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
CN103735676B (en) | A kind of compound Chinese medicinal preparation for the treatment of traumatic injury and its preparation method and application | |
CN115400171B (en) | Traditional Chinese medicine composition for treating wind-cold type common cold and preparation method thereof | |
CN108186758A (en) | A kind of Chinese medicine composition of qi and activate blood circulation and preparation method thereof | |
CN107260890A (en) | A kind of compound quick-acting is enriched blood blood-forming agent and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: HEKANG PHARMACEUTICAL LLC, CHENGDU Free format text: FORMER OWNER: LI WENJUN Free format text: FORMER OWNER: CHEN JIN Effective date: 20050826 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050826 Address after: High tech Zone Gaopeng Avenue in Chengdu city in Sichuan province No. 5, park B block, floor 3 Applicant after: Hekang Medicine Industry Co., Ltd., Chengdu Address before: 2, building 6, building 12, building 7, wash Bridge Street, No. 6-11, Sichuan, Chengdu, Wuhou District Applicant before: Li Wenjun Co-applicant before: Chen Jin |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Hekang Medicine Industry Co., Ltd., Chengdu Document name: Second notice of examination advice |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081205 Address after: Room 420, Goldman Sachs center, No. 2 Gaosheng East Road, Sichuan, Chengdu Patentee after: Chen Jin Address before: High tech Zone of Chengdu City, Sichuan Province, Gaopeng Road No. 2 Patentee before: Hekang Medicine Industry Co., Ltd., Chengdu |
|
ASS | Succession or assignment of patent right |
Owner name: CHEN JIN Free format text: FORMER OWNER: HEKANG PHARMACEUTICAL LLC, CHENGDU Effective date: 20081205 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Chengdu Jinhua Pharmaceutical Co., Ltd. Assignor: Chen Jin Contract fulfillment period: 2009.3.18 to 2019.3.17 Contract record no.: 2009510000135 Denomination of invention: Cardiac and cerebral vascular disease treating medicinal composition Granted publication date: 20080903 License type: Exclusive license Record date: 20091029 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.3.18 TO 2019.3.17; CHANGE OF CONTRACT Name of requester: CHENGDU JINHUA PHARMACEUTICAL CO., LTD Effective date: 20091029 |
|
DD01 | Delivery of document by public notice |
Addressee: Chen Jin Document name: Notification of Termination of Patent Right |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080903 Termination date: 20121003 |